Ticagrelor enhances the cardioprotective effects of ischemic preconditioning in stable patients undergoing percutaneous coronary intervention: the TAPER-S randomized study
- stopped early
- Stopped early because the primary endpoint was met at a pre-specified interim analysis
Authors' conclusion
Ticagrelor enhances the cardioprotective effects of IPC compared with clopidogrel in stable patients with CAD undergoing PCI.
Study context
- Population
- Stable patients with coronary artery disease (CAD) requiring fractional flow reserve-guided percutaneous coronary intervention (PCI) of intermediate epicardial coronary lesions
- Participants
- 53 patients
- Comparison
- Ticagrelor vs clopidogrel
- Primary endpoint
- ΔST-segment elevation on intracoronary ECG during two-step sequential coronary balloon inflations (indirect marker of ischemic preconditioning cardioprotection)
Methodological detailsProspective Randomized Open Blinded End-points (PROBE), prespecified interim analysis
- Prospective Randomized Open Blinded End-points (PROBE)
- Prespecified interim analysis
Primary result
As reported in the abstract
ΔST-segment elevation
- Ticagrelor vs Clopidogrel: P < 0.0001
- Pre-specified interim analysis
Further findings
Angina score during coronary balloon inflations
- Lower angina score with ticagrelor
Coronary microvascular resistance
- No difference between groups
Adenosine serum concentrations
- Increased with ticagrelor vs clopidogrel
Original publication
Ticagrelor enhances the cardioprotective effects of ischemic preconditioning in stable patients undergoing percutaneous coronary intervention: the TAPER-S randomized study. Eur Heart J Cardiovasc Pharmacother. Published 24 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →